DiaMedica Therapeutics Inc. 8-K

What Happened DiaMedica Therapeutics Inc. announced the results of its 2026 Annual General Meeting of Shareholders held May 20, 2026 (Form 8-K filed May 21, 2026). Shareholders approved all four proposals on the agenda: the re-election of seven incumbent directors, ratification of Baker Tilly US, LLP as the company’s independent registered public accounting firm for 2026, an advisory (non-binding) approval of executive compensation, and an amendment to increase the Amended & Restated 2019 Omnibus Incentive Plan by 3,500,000 shares.

Key Details

• Directors re-elected (votes For / Withheld; broker non-votes: 11,180,693): Michael Giuffre, M.D. 10,119,610 / 229,027; Rick Kuntz, M.D., M.Sc. 10,166,733 / 181,904; Tanya Lewis 10,136,190 / 212,447; Daniel O’Connor 5,217,758 / 5,130,879 (notably close); James Parsons 10,035,604 / 313,033; Rick Pauls 10,178,755 / 169,882; Charles Semba, M.D. 10,161,380 / 187,257.
• Auditor ratified: Baker Tilly US, LLP appointed with 20,950,404 votes For and 578,926 votes Withheld (no broker non-votes).
• Executive compensation (advisory): Approved with 9,928,381 For, 271,093 Against, 149,163 Abstain; broker non-votes: 11,180,693.
• Omnibus plan amendment: Approved to add 3,500,000 shares (9,693,413 For, 510,487 Against, 144,737 Abstain; broker non-votes: 11,180,693).

Why It Matters For investors, the results mean continuity of DiaMedica’s current board and independent auditor for 2026, and shareholder backing for the company’s executive pay program (advisory/non-binding). Approval of the 3.5 million‑share increase to the Omnibus Incentive Plan expands the pool available for future equity awards; if granted, those awards could affect share count and dilution over time. The close vote for director Daniel O’Connor signals meaningful shareholder opposition in that race, which could be relevant to governance watchers.